Parameters of fibrinolysis in postmenopausal women taking oral and transdermal hormone replacement therapy

Advances in Clinical and Experimental Medicine

Volumn 19, Issue 2, 2010, Pages 203-210

  Ruszkowska, Barbara ^a   Manysiak, Sławomir ^a   Małecka, Beata ^a   Dymek, Grazyna ^a   Rość, Danuta ^a   Odrowa̧z Sypniewska, Grazyna ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Fibrinolysis; Hormone replacement therapy; Menopause

Indexed keywords

ANTIPLASMIN; D DIMER; ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE ACETATE; FIBRINOGEN; NORETHISTERONE ACETATE; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; FIBRINOLYSIS; HEMOSTASIS; HORMONE DEFICIENCY; HORMONE RESPONSE; HORMONE SUBSTITUTION; HUMAN; HUMAN EXPERIMENT; POSTMENOPAUSE; PROTEIN BLOOD LEVEL;

EID: 77952991795     PISSN: 1230025X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Stefańczyk L, Owczarek D, Stachowiak G, Stetkiewicz T: Evaluation of fibrinolysis in menopausal women suffering from lower limb deep vein thrombosis. Przegl Menopauz 2004, 3, 73-77.
2. Żekanowska E, Ruszkowska B: The role of u-PA/u-PAR system in human physiology. Ann Acad Med Bydgost 2004,18, 27-31.
3. Cierniewski CS: Progress in knowledge about fibrinolysis regulation. Acta Haemat Pol 1994, 25, 15-25.
4. Stachowiak G, Stetkiewicz T, Polać I, Sobczuk A, Jȩdrzejczyk S, Pertyński T: The role of plasminogen activator inhibitor 1 (PAI-1) after menopause - the influence hormonal therapy of his period. Przegl Menopauz 2005, 6, 17-21.
5. Cioch M, Dmoszyńska A, Hus I: Urokinase-type plasminogen activator (uPA) and urokinase-type plasminogen activator receptor (uPAR) in pathology and prognosis of malignancies. Acta Haemat Pol 1999,30, 249-256.
6. Pertyński T, Stachowiak G, Stetkiewicz T: Role of the gynaecologist in pre- and perimenopausal period. Przegl Menopauza 2007, 2, 63-69.
7. World Health Organization research on the menopause in the 1990s. Report of a WHO Scientific Group Organ. Technical Report Series, Geneva 1996, 866, 1-107.
8. Collejon RD, Franceschini AS, Montes BM, Toloi RM: Hormone replacement therapy and hemostasis: Effects in Brazilian postmenopausal women. Maturitas 2005, 52, 249-255.
9. Pripp U, Eriksson-Berg M, Orth-Gomer K, Schenck-Gustafsson K, Landgren BM: Does body mass index, smoking, lipoprotein levels, surgically induces menopause, hormone replacement therapy, tears since menopause or age affect hemostasis in postmenopausal women? Gender Medicine 2005, 2, 88-95.
10. Szymański LM, Kessler CM, Ferngall B: Relationship of physical fitness, hormone replacement therapy, and hemostatic risk factors in postmenopausal women. J Appl Physiol 2005, 98, 1341-1348. (Pubitemid 40396509)
11. Shah MG, Maibach HI: Estrogen and skin. An overview. Am J Clin Dermatol 2001, 2, 143-149.
12. Wojnowska D, Juszkiewicz-Borowiec M, Chodorowska G: Menopause and skin aging. Post Dermatol Alergol 2006, 3, 149-156.
13. Barett-Connor E, Stuenkel CA: Hormonal replacement therapy (HRT) - risk and benefits. Inter J Epidem 2001, 30, 423-426. (Pubitemid 32600222)
14. Pertyński T, Stachowiak G: Choosing the route of drug administration for hormone therapy of the menopausal period - when is it worth to truck tablets for patches? Przegl Menopauz 2006, 5, 323-328.
15. Pertyński T, Stachowiak G: Transdermal applying of 17β-oestradiol. Is this progress in hormone replacement therapy? Przegl Menopauz 2004, 3, 41-48.
16. Rydzkowska-Zalewska D, Rość D, Ponikowska I, Michalski A, Graczykowska Kaczorowska A, Rydzkowski M: Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy. Pol Merk Lek 2001, 65, 414-417.
17. Post MS, van der Mooren MJ, van Baal WM, Blankenstein MA, Merkus HM, Kroeks MV, Franke HR, Kenemans P, Stehouwer CD: Effects of low-dose oral and transdermal estrogen replacement therapy on hemo-static factors in healthy postmenopausal women: a randomized placebo-controlled study. Am J Obstet Gynecol 2003, 189, 1221-1227. (Pubitemid 37542149)
18. Kanda N, Watanabe S: Regulatory roles of sex hormones in cutaneous biology and immunology. J Dermatol Sci 2005, 38, 1-7. (Pubitemid 40410625)
19. Soszka T: Hormone replacement therapy effects on the hemostatic system. Przegl Menopauz 2004, 1, 12-22.
20. Stachowiak G, Faflik U, Stetkiewicz T, Pertyński T: Cardiovascular diseases in women - impact of the menopausal period. Przegl Menopauz 2006, 6, 382-387. (Pubitemid 46188993)
21. Juhan-Vague I, Roul C, Alessi MC: Increased plasminogen activator inhibitor activity in non-insulin dependent diabetic patients. Relationship with plasma insulin. Thromb Haemost 1989, 61, 370-373.
22. Stachowiak G, Owczarek D, Pertyński T: The influence of 17β-oestradiol and norethisterone acetate given transermally and low doses acetylosalicylic acid on some selected parameters of coagulation and fibrinolysis in menopausal women with some risk factors for coronary heart disease. Przegl Menopauz 2006, 3, 159-164.
23. Stachowiak G, Stetkiewicz T, Jȩdrzejczyk S, Sobczuk A, Makuła A, Pertyński T: Genetic polymorphisms in coagulation and fibrinolysis systems versus thromboembolic risk of estrogen-progestin therapies in women. Przegl Menopauz 2005, 5, 59-64.
24. Chandler W, Alessi MC, Aillaud M, Henderson P, Vague P, Juhan-Vague I: Clearance of tissue plasminogen activator (TPA) and TPA/plasminogen activator inhibitor type 1 (PAI-1) complex: relationship to elevated TPA antigen in patients with high PAI-1 activity levels. Circulation 1997, 96, 761-768. (Pubitemid 27329607)
25. Collen D, Lijnen HR: Molecular basis of fibrinolysis, as relevant for thrombolytic therapy. Thromb Haemost 1995, 74, 167-171.
26. Takada A, Takada Y, Urano T: The physiological aspects of fibrinolysis. Thromb Res 1994, 76, 1-31.
27. Saitoh O, Matsumoto H, Sugimori K, Sugi K, Nakagawa K, Miyoshi H, Hirata I, Matsuse R, Uchida K, Ohshiba S: Intestinal protein loss and bleeding assessed by fecal hemoglobin, transferrin, albumin, and alpha-1-antitrypsin levels in patients with colorectal diseases. Digestion 1995, 56, 67-75.
28. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimes on heart disease risk factors in postmenopausal women. JAMA 1995, 271, 199-208.
29. Andersen LF, Gram J, Skouby SO, Jespersen J: Effects of hormone replacement therapy on hemostatic cardiovascular risk factors. Am J Obstet Gynecol 1999, 180, 283-289.